CRESTOVO
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut microbiome. Crestovo is advancing the foundational clinical research of the company’s academic collaborators, Dr. Thomas Borody, Dr. Alexander Khoruts and Dr. Michael Sadowsky, which demonstrated in-human validation of an orally-available, microbiota-based product across a variety of serious diseases and unmet medical needs, including recurrent CDI. Crestovo’s lead Full-Spectrum Microbiota™ (FSM™) product, CP101, is currently being evaluated in the PRISM 3 clinical trial in patients with recurrent CDI.
CRESTOVO
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.crestovo.com
Status:
Active
Contact:
(800) 881-9361
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Cloudflare Hosting Cloudflare DNS Pound Sterling Japanese Yen Mimecast
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Official Site Inspections
http://www.crestovo.com
- Host name: 104.21.54.81
- IP address: 104.21.54.81
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Crestovo" on Search Engine
Finch Therapeutics and Crestovo Announce Merger to Form …
Oct 23, 2017 SOMERVILLE and CAMBRIDGE, MA—October 23, 2017 — Finch Therapeutics, a privately held microbiome engineering company and Crestovo, a …See details»
Finch Therapeutics & Crestevo Merge to Form Fully …
Oct 25, 2017 Finch Therapeutics, a privately held microbiome engineering company and Crestovo, a privately held, clinical-stage …See details»
Crestovo Company Profile 2024: Valuation, Investors, …
Information on acquisition, funding, investors, and executives for Crestovo. Use the PitchBook Platform to explore the full profile.See details»
Microbiome merger flies Finch into phase 2 trial | Fierce Biotech
Oct 23, 2017 The combined company, which will take Finch’s name, starts life with Crestovo’s mid-phase Clostridium difficile candidate, a large-scale stool donation …See details»
Finch, Crestovo merger pushes forward C diff therapeutic
Oct 24, 2017 Microbiota engineering company Finch Therapeutics Inc and biopharma Crestovo have merged to create a fully-integrated microbiota company. The deal will …See details»
Finch Therapeutics and Crestovo Announce Merger to …
Oct 23, 2017 SOMERVILLE, Mass. & CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Finch Therapeutics, a privately held microbiome engineering company and Crestovo, a …See details»
Takeda's Partner Merges With Crestovo to Form Finch
Published: Oct 23, 2017 By Alex Keown. Two privately-held biotechs have merged to tackle recurrent C. difficile infections. Finch Therapeutics and Cambridge, Mass.-based …See details»
Finch Therapeutics acquires Crestovo - 2017-10-23
Acquired Organization: Crestovo Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota that harnesses the human gut microbiome. …See details»
Crestovo Doses Patients In PRISM 3, A Clinical Trial Of CP101, A ...
Jun 27, 2017 CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Crestovo, a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that …See details»
Crestovo - Products, Competitors, Financials, Employees, …
Overview & Products. Financials. People. Stage. Merger | Merged. About Crestovo. Crestovo leverages its Full-Spectrum Microbiota platform to develop therapeutics that …See details»
Finch Therapeutics, Inc acquired Crestovo. - MarketScreener
Oct 22, 2017 Finch Therapeutics, Inc acquired Crestovo on October 23, 2017. As per the terms of agreement, Finch and Crestovo will form new entity i.e., Finch Therapeutics …See details»
Finch Therapeutics Raises $36 Million Series B, Bringing
Mar 1, 2018 In October 2017, it merged with Crestovo, which combined Crestovo’s extensive intellectual property assets and late-stage candidate for recurrent C. difficile …See details»
SEC.gov | HOME
Crestovo also acquired 735,294 shares of Common Stock at a price of $17.00 per share in the initial public offering. (d) No person other than the Reporting Persons is known to …See details»
Home — Finch Therapeutics
Apr 25, 2023 Finch, an early pioneer in the microbiome field, has established a portfolio of innovative microbiome assets with potential applicability to a wide range of product …See details»
Crestovo - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota that harnesses the human gut microbiome.See details»
Create an Organization and Manage Users | Oculus Developers
Create an Organization and Manage Users | Oculus Developers. Describes how to set up a Meta Quest developer organization and its members.See details»
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a ...
Jun 27, 2017 CAMBRIDGE, Mass. – Crestovo, a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut …See details»
How to Manage a Creative Organization | Scientific American
October 21, 2014. 7 min read. How to Manage a Creative Organization. Harvard Business School’s Linda Hill explains how to unleash “collective genius” By Gareth Cook. What …See details»
The Creative Organization - Visioning / Brand Strategy / Concept ...
The Creative Organization is a brand strategy consultancy with offices in New York and London. We believe that creative intelligence is your organization’s most potent …See details»
thecreativeorganization.com | Professional Development
The Power of Practice. In his bestselling book, Outliers, Malcolm Gladwell repeatedly mentions the “10,000-Hour Rule,” claiming that the key to success in any field is, to a …See details»